- Current report filing (8-K)
August 17 2010 - 1:38PM
Edgar (US Regulatory)
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): August 13,
2010
TIENS
BIOTECH GROUP (USA), INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32477
|
|
75-2926439
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
|
|
Identification
Number)
|
No. 6, Yuanquan Road, Wuqing
New-Tech Industrial Park, Tianjin, China
301700
(Address
of principal executive offices)
Registrant's
telephone number, including area code:
(
86
)
22
-
8213-
7335
Not
applicable
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2.):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On August
13, 2010, the Board of Directors of Tiens Biotech Group (USA), Inc. (the
“Company”) appointed Jinyuan Li, Chairman, Chief Executive Officer and President
of the Company, as Acting Chief Financial Officer of the Company to fill the
vacancy created by the resignation of Manbo He, the Company’s former Chief
Financial Officer, who resigned on June 17, 2010.
Other
information required by this Item regarding Mr. Li is omitted, as it has been
previously reported.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
TIENS
BIOTECH GROUP (USA), INC.
|
|
|
|
Date: August
17, 2010
|
By:
|
/s/ Jinyuan Li
|
|
|
Name: Jinyuan
Li
|
|
|
Title: Chairman,
Chief Executive
Officer
and President
|
3
Tiens Biotech GR Usa (AMEX:TBV)
Historical Stock Chart
From May 2024 to Jun 2024
Tiens Biotech GR Usa (AMEX:TBV)
Historical Stock Chart
From Jun 2023 to Jun 2024